- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05786014
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
August 9, 2023 updated by: Siddartha Angadi, University of Virginia
A Feasibility Study to Examine Two Remotely-monitored Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
The purpose of this study is to determine if exercise preconditioning can mitigate the off target effects of chemotherapy treatment on measures of cardiovascular function, inflammatory responses, and quality of life.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Breast cancer is the most common malignancy affecting women in the US and survivors experience long-term health effects of chemotherapy.
Exercise training is an efficacious treatment for preserving functional capacity and has shown promise in mitigating cardiac toxicity of breast cancer chemotherapy.
However, supervised exercise is not a practical solution for all breast cancer survivors, as medically monitored exercise facilities are poorly dispersed in the US and poorly utilized by cancer patients.
To improve reach of these programs, remotely monitoring exercise sessions may be necessary.
However, effects of remotely-monitored exercise conditioning before and during adjuvant/neoadjuvant chemotherapy on cardiotoxic outcomes are unknown.
Our study aims to address this gap by testing the feasibility of two types of remotely-monitored exercise interventions, an exercise bicycle intervention compared to a brisk walking intervention, in 20 UVA Breast Cancer Clinic patients undergoing cardiotoxic chemotherapies.
Remotely-monitored exercise training will start one week prior to chemotherapy (preconditioning) and continue throughout adjuvant or neoadjuvant chemotherapy (which is typically 4 months in duration).
Our multidisciplinary research team proposes four aims: 1) Determine the extent to which eligible patients can be successfully recruited, randomized, and retained; 2) Assess VO2peak, echocardiography derived left ventricular ejection fraction and left ventricular global longitudinal strain among these patients at baseline and at ~4 months; 3) Examine treatment engagement and intervention acceptability; and 4) Explore the relationship between engagement in the exercise training and psychosocial function.
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Siddhartha S Angadi, PhD
- Phone Number: 434-243-7466
- Email: ssa2w@virginia.edu
Study Contact Backup
- Name: Zach Leicht, MS
- Phone Number: 434-243-8677
- Email: njn3wg@virginia.edu
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- University of Virginia University Hospital
-
Contact:
- Siddhartha S Angadi, PhD
-
Contact:
- Zach Leicht, MS
- Email: njn3wg@virginia.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18 years or over
- diagnosis of breast cancer (Stage I-III or IV with minimal burden) and prescribed chemotherapy (TC (Docetaxel/Cyclophosphamide), AC (Doxorubicin/Cyclophosphamide followed by Paclitaxel), TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab), TCH (Docetaxel/Carboplatin/Trastuzumab) with or without Pembrolizumab)
- Physician clearance for exercise training
- Speak/understand English
Exclusion Criteria:
- previous treatment with cardiotoxic chemotherapy
- medical/orthopedic comorbidities that preclude stationary cycling
- significant cardiac/renal/hepatic/hematological/pulmonary disease precluding exercise training
- unstable angina or myocardial infarction within 4-weeks prior to treatment
- complex ventricular arrhythmias or New York Heart Association class IV symptoms
- symptomatic severe aortic stenosis
- acute pulmonary embolus
- acute myocarditis
- History of untreated high-risk proliferative retinopathy
- History of retinal hemorrhage
- uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 120 mm Hg)
- severe baseline electrolyte abnormalities
- medication non-compliance
- uncontrolled metabolic disease (diabetes with fasting blood sugar >300 mg/dl, thyrotoxicosis, myxedema)
- symptomatic peripheral vascular disease
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Intensity Interval Exercise
Subjects will receive a recumbent bike to be delivered and assembled to their home as well as a heart rate monitor and activity tracker.
Subjects will undergo high intensity interval exercise 3 days a week, with the goal of achieving 85-90% of their heart rate max.
Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
|
Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home.
The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR.
Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR.
Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose.
Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
|
Experimental: Moderate Intensity Walking
Subjects allocated to moderate intensity walking will be given a gift card to purchase a paid of running shoes.
A chest-based heart rate monitor and an activity tracker watch will be provided.
Subjects will aim to achieve 150 minutes a week of moderate intensity walking.
Subjects will also be receiving text messages, phone calls, and emails from study staff to gauge and encourage subject participation and physical activity.
|
Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity.
Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test).
The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging.
Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject Retention Percentage
Time Frame: 22 Weeks
|
This is a feasibility study designed to determine the extent to which eligible patients can be successfully recruited, randomized, and retained.
Endpoint data will be used to justify and provide point estimates for a fully powered study.
Retention will be measured as a percentage of those enrolled who complete the study interventions.
|
22 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VO2peak
Time Frame: 22 Weeks
|
Change in VO2peak (L/min) measured at pre-chemotherapy and post chemotherapy
|
22 Weeks
|
Global Longitudinal Strain
Time Frame: 22 Weeks
|
Global longitudinal strain (%) will be used to assess changes in cardiac contractile function and be measured by echocardiogram at pre-chemotherapy and post-chemotherapy
|
22 Weeks
|
Ejection Fraction
Time Frame: 22 Weeks
|
Ejection fraction (%) will be used to assess changes in cardiac contractile function and be measured by echocardiogram at pre-chemotherapy and post-chemotherapy
|
22 Weeks
|
Diastolic Function
Time Frame: 22 Weeks
|
E' and A' (cm/s) will be used to calculate the E'/A' ratio to assess for diastolic dysfunction and be measured by echocardiogram at pre-chemotherapy and post-chemotherapy
|
22 Weeks
|
Brachial Artery Endothelium-Dependent Flow-Mediated Dilation
Time Frame: 22 Weeks
|
Changes in endothelial function as measured by brachial artery endothelium-dependent flow-mediated dilation (%) at pre-chemotherapy and post-chemotherapy
|
22 Weeks
|
Carotid-Femoral Pulse Wave Velocity
Time Frame: 22 Weeks
|
Changes in arterial stiffness as measured by carotid-femoral pulse wave velocity (m/s) at pre-chemotherapy and post-chemotherapy
|
22 Weeks
|
Blood pressure
Time Frame: 22 Weeks
|
Brachial systolic and diastolic blood pressures (mmHg) will be measured at baseline and post-chemotherapy.
|
22 Weeks
|
Lipid panels
Time Frame: 22 Weeks
|
A lipid panel will be performed to measure total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoprotein (mg/dl) to assess changes in cardiometabolic health at pre-chemotherapy and post-chemotherapy
|
22 Weeks
|
Inflammation/Immune cell concentrations in peripheral circulation.
Time Frame: 22 Weeks
|
Various markers of inflammation and immune cells will be measured at baseline, pre-chemo (following exercise pre-conditioning), midway through patient's prescribed treatment, and post-intervention to determine changes.
|
22 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2023
Primary Completion (Estimated)
January 15, 2025
Study Completion (Estimated)
March 15, 2025
Study Registration Dates
First Submitted
March 13, 2023
First Submitted That Met QC Criteria
March 23, 2023
First Posted (Actual)
March 27, 2023
Study Record Updates
Last Update Posted (Actual)
August 14, 2023
Last Update Submitted That Met QC Criteria
August 9, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 220287
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on High Intensity Interval Exercise
-
Laboratoire des Adaptations Métaboliques à l'Exercice...CREPS Auvergne Rhône-Alpes / VichyCompletedOverweight | PostmenopausalFrance
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Liverpool John Moores University; Australian Catholic UniversityCompletedPolycystic Ovary SyndromeAustralia, Norway
-
State University of New York at BuffaloRecruitingSpinal Cord Injuries | Cognition | Autonomic Nervous System DiseaseUnited States
-
New York State Psychiatric InstituteColumbia UniversityCompleted
-
Steno Diabetes Center CopenhagenRecruiting
-
University of North Carolina, Chapel HillNorth Carolina Diabetes Research CenterCompletedDiabetes Mellitus, Type 1United States
-
Nationwide Children's HospitalCompleted
-
Kaohsiung Medical University Chung-Ho Memorial...Ministry of Science and Technology, TaiwanRecruiting
-
Ahlia UniversityCairo UniversityCompletedObesity | Diabetes | Exercise | Nonalcoholic Fatty Liver DiseaseEgypt